Finance

Lists
Why is MLYS up ၃.၀၅%?
Dive Deeper
MLYS:NASDAQ
Mineralys Therapeutics Inc
၂၀.၉၂ US$
+၃.၀၅%
(+၀.၆၂) 1D
၂၀.၉၂ US$
၀.၀၀% (၀.၀၀)
After hours
Closed: အောက် ၁၉, GMT-၄ ၁၆:၀၀:၀၀  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MLYS...
Open
၂၀.၅၇ US$
High
၂၁.၁၁ US$
Low
၂၀.၂၇ US$
Mkt. cap
၁၈၄.၉၅ ဋေ
Avg. vol.
၁.၄၈ သန်း
Volume
၀.၀၀
52-wk high
၄၇.၆၅ US$
52-wk low
၂၀.၁၂ US$
EPS
-၄.၂၄ US$
Beta
၀.၆၉
Shares outstanding
၈.၈၄ ကုဋေ
No. of employees
၇၆
Open
၂၀.၅၇ US$
High
၂၁.၁၁ US$
Low
၂၀.၂၇ US$
Mkt. cap
၁၈၄.၉၅ ဋေ
Avg. vol.
၁.၄၈ သန်း
Volume
၀.၀၀
52-wk high
၄၇.၆၅ US$
52-wk low
၂၀.၁၂ US$
EPS
-၄.၂၄ US$
Beta
၀.၆၉
Shares outstanding
၈.၈၄ ကုဋေ
No. of employees
၇၆
News stories
From web sources and news partners
Investing.com
Investing.com
·
ပြီးခဲ့သည့် ၉ နာရီ
Mineralys appoints two directors ahead of drug launch
Simply Wall Street
Simply Wall Street
·
ပြီးခဲ့သည့် ၁၅ နာရီ
Did Phase 3 Blood Pressure Data Just Shift Mineralys Therapeutics Stock Investment Narrative?
About Mineralys Therapeutics Inc
CEO-
Employees၇၆
Founded၂၀၁၉
Headquarters-
Sector-
Analyst ratings
Based on 7 analysts giving stock ratings to MLYS in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for MLYS in the last 3 months.
Highest
Current ၂၀.၉၂ US$
၅၆.၀၀ US$ (+၁၆၇.၆၉%)
Average
၄၇.၈၆ US$ (+၁၂၈.၇၈%)
Lowest
၂၉.၀၀ US$ (+၃၈.၆၂%)
Analyst
Recommendation
Action
Price target
Projected
Date
Jason Gerberry
Bank of America Securities
Buy
Maintained
၄၉.၀၀ US$
+၁၃၄.၂%
10/12/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
၅၆.၀၀ US$
+၁၆၇.၇%
10/12/2026
Unknown Analyst
UBS
Hold
Initiated
၂၉.၀၀ US$
+၃၈.၆%
10/11/2026
Alice Nettleton
UBS
Hold
Initiated
၂၉.၀၀ US$
+၃၈.၆%
10/12/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
၅၂.၀၀ US$
+၁၄၈.၆%
08/12/2026
Richard Law CFA
Goldman Sachs
Buy
Maintained
၄၀.၀၀ US$
+၉၁.၂%
08/12/2026
Mohit Bansal
Wells Fargo
Buy
Maintained
၅၅.၀၀ US$
+၁၆၂.၉%
08/12/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
၅၅.၀၀ US$
+၁၆၂.၉%
08/12/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
၅၄.၀၀ US$
+၁၅၈.၁%
08/12/2026
Annabel Samimy
Stifel Nicolaus
Buy
Maintained
၅၂.၀၀ US$
+၁၄၈.၆%
05/07/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
၄၂.၀၀ US$
+၁၀၀.၈%
05/07/2026
Tara Bancroft
TD Cowen
Buy
Maintained
-
-
05/06/2026
Last report
၂၀၂၆ ဩ ၁၁
Fiscal period
Q2 2026
-၂.၈၅ US$ / -၀.၅၄ US$
-၄၃၂.၇၁%miss
Revenue / Est. (USD)
- / ၀.၀၀
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
၂၀၂၅ စက်
၂၀၂၅ ဒီ
၂၀၂၆ မတ်
၂၀၂၆ ဇွန်
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
၃.၁၄ ကုဋေ
၂.၄၄ ကုဋေ
၂.၄၄ ကုဋေ
၂၂.၁၄ ကုဋေ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
၉.၆၈ သန်း
၁.၃၉ ကုဋေ
၂.၁၀ ကုဋေ
၂.၄၇ ကုဋေ
Operating expense
၄.၁၁ ကုဋေ
၃.၈၃ ကုဋေ
၄.၅၃ ကုဋေ
၂၄.၆၀ ကုဋေ
Total operating expenses
၄.၁၁ ကုဋေ
၃.၈၃ ကုဋေ
၄.၅၃ ကုဋေ
၂၄.၆၀ ကုဋေ
Operating income
-၄.၁၁ ကုဋေ
-၃.၈၃ ကုဋေ
-၄.၅၃ ကုဋေ
-၂၄.၆၀ ကုဋေ
Other non operating income
၄.၀၀ ထောင်
၁.၀၀ ထောင်
၅.၀၀ ထောင်
၁.၃၀ သောင်း
EBT including unusual items
-၃.၆၉ ကုဋေ
-၃.၂၂ ကုဋေ
-၃.၉၃ ကုဋေ
-၂၄.၁၁ ကုဋေ
EBT excluding unusual items
-၃.၆၉ ကုဋေ
-၃.၂၂ ကုဋေ
-၃.၉၃ ကုဋေ
-၂၄.၁၁ ကုဋေ
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-၃.၆၉ ကုဋေ
-၃.၂၂ ကုဋေ
-၃.၉၃ ကုဋေ
-၂၄.၁၁ ကုဋေ
Net profit margin
-
-
-
-
Earnings per share
-၀.၅၂
-၀.၄၀
-၀.၄၇
-၂.၈၅
Interest and investment income
၄.၂၀ သန်း
၆.၀၄ သန်း
၆.၀၀ သန်း
၄.၉၆ သန်း
Interest expense
-
-
-
-
Net interest expenses
၄.၂၀ သန်း
၆.၀၄ သန်း
၆.၀၀ သန်း
၄.၉၆ သန်း
Depreciation and amortization charges
-
-
-
-
EBITDA
-၄.၁၁ ကုဋေ
-၃.၈၃ ကုဋေ
-၄.၅၃ ကုဋေ
-၂၄.၆၀ ကုဋေ
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google အက်ပ်များ